CASI Pharmaceuticals (CASIF) Profit After Tax (2022 - 2025)

CASI Pharmaceuticals (CASIF) has 4 years of Profit After Tax data on file, last reported at -$83.1 million in Q4 2025.

• Quarterly Profit After Tax fell 478.1% year-over-year to -$83.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$96.6 million (down 378.08% YoY) and the FY2025 annual result came in at -$48.1 million, down 22.42% from the prior year.
• Profit After Tax eased to -$83.1 million in Q4 2025, from -$10.9 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $10.8 million in Q1 2025 to a low of -$83.1 million in Q4 2025.
• A 4-year average of -$11.5 million and a median of -$7.9 million in 2022 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2024 — Profit After Tax surged 263.4% — and 2025, when it plunged 478.1%.
• Tracing CASIF's Profit After Tax over 4 years: stood at -$19.3 million in 2022, then soared by 65.91% to -$6.6 million in 2023, then tumbled by 117.96% to -$14.4 million in 2024, then sank by 478.1% to -$83.1 million in 2025.
• The last three Profit After Tax figures came in at -$83.1 million (Q4 2025), -$10.9 million (Q3 2025), and -$13.4 million (Q2 2025), per Business Quant data.